January 13, 2023

Flooid Announces Strategic Partnership with FreedomPay to Expand Global Reach

The partnership will bring enhanced commerce functionality to Retailers around the world.

London, England, Jan. 13, 2023 (GLOBE NEWSWIRE) — Flooid today announces a strategic partnership with FreedomPay, the global leader in Next Level Commerce, to bring industry-leading Retail solutions to merchants globally.

Powered by FreedomPay, Flooid allows merchants to connect their retail channels, removing barriers between online and in-store payments. FreedomPay’s data-driven commerce platform grants merchants access to valuable analytics and Business Intelligence platform to drive further customer engagement and loyalty through targeted offers and incentives, all within a frictionless integrated payment solution.

“Through this partnership with FreedomPay, we are bringing enhanced innovation, choice, and flexibility to retailers on the Flooid platform,” said Donna Stevens, Senior VP of Product and Marketing at Flooid. Our goal is to empower merchants with the tools they need to provide the best shopping experience to consumers globally.”

The FreedomPay platform enables enterprises to provide a consistent payment experience for their customers globally, creating a seamless and flexible retail experience managing security, data and loyalty all from a single, unified tech stack.

“The partnership between FreedomPay and Flooid will bring a world-class commerce experience to retailers and shoppers around the globe,” said Liesl Smith, Senior VP of Marketing and Sales Enablement at FreedomPay. “Together we are committed to delivering a seamless payment experience to customers, enabling an innovative and seamless omnichannel payment environment.”

About FreedomPay

FreedomPay’s Next Level Commerce platform transforms existing payment systems and processes from legacy to leading edge. As the premier choice for many of the largest companies across the globe in retail, hospitality, lodging, gaming, sports and entertainment, foodservice, education, healthcare and financial services, FreedomPay’s technology has been purposely built to deliver rock solid performance in the highly complex environment of global commerce. The company maintains a world-class security environment and was first to earn the coveted validation by the PCI Security Standards Council against Point-to-Point Encryption (P2PE/EMV) standard in North America. FreedomPay’s robust solutions across payments, security, identity, and data analytics are available in-store, online and on-mobile and are supported by rapid API adoption. The award winning FreedomPay Commerce Platform operates on a single, unified technology stack across multiple continents allowing enterprises to deliver an innovative Next Level experience on a global scale. www.freedompay.com

About Flooid

Flooid helps retailers create the seamless shopping experiences customers demand. Flooid’s unified commerce platform empowers merchants to sell to customers flexibly and consistently wherever they are and however they choose to shop. Our best of breed open ecosystem givers retailers the power to connect leading retail tech partners with a single unified commerce platform to engage with your shoppers, sell more effectively across channels and adapt to retail shopping changes we have yet to imagine.

Jennifer Tayebi
Hill+Knowlton Strategies for FreedomPay
+1 734 395 0780
Jennifer.Tayebi@hkstrategies.com

GlobeNewswire Distribution ID 8729158

January 13, 2023

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Avaya Holdings Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AVYA, AVYAW

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Avaya Holdings Corp. (NYSE: AVYA) (OTC: AVYAW) between November 22, 2021 and November 29, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 6, 2023.

SO WHAT: If you purchased Avaya securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Avaya class action, go to https://rosenlegal.com/submit-form/?case_id=8033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s internal control over financial reporting (“ICFR”) was deficient in several areas; (2) as a result of these deficiencies, the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program; (3) the Company’s deteriorating financial condition was likely to raise substantial doubt as to its ability to continue as a going concern; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Avaya class action, go to https://rosenlegal.com/submit-form/?case_id=8033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 8729172

January 13, 2023

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Sabin Vaccine Institute Awarded BARDA Contract With Funding Potential up to $214M for Ebola Sudan and Marburg Vaccines

The Sabin Vaccine Institute will produce up to 100,000 doses of Sabin’s Ebola Sudan vaccine as part of a new, multi-year contract with BARDA

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:

[email protected]

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b

GlobeNewswire Distribution ID 8728283

January 13, 2023

PM thanks EU for its commitment of $97m for flood affectees

Prime Minister Shehbaz Sharif has thanked the European Union for its commitment of 97 million dollars for Pakistan’s flood affectees.

In a tweet, said that multifaceted relations between Pakistan and the European Union have grown over the decades.

The Prime Minister said European Union continues to remain one of Pakistan’s largest trading and development partners and export destinations.

Source: Radio Pakistan

January 13, 2023

SC, ECP would decide time frame of next elections: Sanaullah

Minister for Interior Rana Sanaullah has said the Supreme Court and Election Commission of Pakistan (ECP) would decide the time frame of the next elections.

Talking to a private television channel, he said the Punjab chief minister forwarded the request to the Punjab governor for dissolving assemblies. The next elections would be conducted after the final decision of the ECP.

Rana Sanaullah said the interim setup would ask the election commission to make necessary arrangements for the next elections in Punjab and Khyber Pakhtunkhwa.

Source: Radio Pakistan

January 13, 2023

Pakistan to soon come out of economic crisis: Ahsan

Minister for Planning and Development Ahsan Iqbal says Pakistan’s economy stands on strong foundations and it would come out of economic crisis very soon.

Talking to BBC, he said despite economic challenges Pakistan will not default in any case.

Speaking about the flood damages in Pakistan, Ahsan Iqbal said over 1700 people died across the country during the torrential rains and floods last year.

He said the rehabilitation and reconstruction continues in the flood hit areas. However, complete recovery would take two to three years’ time.

Source: Radio Pakistan